Fibromyalgia Pipeline Review Report, H1 2019 – Therapeutics Assessment of 13 Companies & 22 Drug Profiles – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Fibromyalgia
– Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

Fibromyalgia – Pipeline Review, H1 2019 provides comprehensive
information on the therapeutics under development for Fibromyalgia
(Central Nervous System), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of
key players involved in therapeutic development for Fibromyalgia
(Fibromyalgia Syndrome) and features dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed,
Preclinical and Unknown stages are 1, 1, 7, 2, 2, 6 and 1 respectively.
Similarly, the Universities portfolio in Phase I and Preclinical stages
comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Fibromyalgia (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Fibromyalgia
  (Central Nervous System) by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Fibromyalgia
  (Central Nervous System) therapeutics and enlists all their major and
  minor projects.
• The pipeline guide evaluates Fibromyalgia (Central Nervous System)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Fibromyalgia (Central Nervous System)

Key Topics Covered:

1. Introduction
2. Report Coverage
3. Fibromyalgia (Fibromyalgia Syndrome) – Overview
4. Fibromyalgia (Fibromyalgia Syndrome) – Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Fibromyalgia (Fibromyalgia Syndrome) – Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type

Fibromyalgia (Fibromyalgia Syndrome) – Companies Involved in
Therapeutics Development

• Abide Therapeutics Inc
• Aptinyx Inc
• Astellas Pharma Inc
• Grunenthal GmbH
• Innovative Med Concepts LLC
• Intec Pharma Ltd
• Jiangsu Hengrui Medicine Co Ltd
• Luye Pharma Group Ltd
• Merck & Co Inc
• Pfizer Inc
• Prismic Pharmaceuticals Inc
• Tetra Bio-Pharma Inc
• Vitality Biopharma Inc

Fibromyalgia (Fibromyalgia Syndrome) – Drug Profiles

• (cannabidiol + dronabinol) – Drug Profile
• (celecoxib + famciclovir) – Drug Profile
• ABX-1626 – Drug Profile
• AS-1069562 – Drug Profile
• ASP-0819 – Drug Profile
• faxeladol – Drug Profile
• LY-03012 – Drug Profile
• mirtazapine ODT – Drug Profile
• MS-11 – Drug Profile
• naltrexone hydrochloride – Drug Profile
• NP-013 – Drug Profile
• NYX-2925 – Drug Profile
• palmidrol – Drug Profile
• Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central
  Nervous System – Drug Profile
• PPP-001 – Drug Profile
• pregabalin ER – Drug Profile
• pregabalin SR – Drug Profile
• Small Molecule 1 to Agonize CB1 and CB2 for Chronic Pain and
  Fibromyalgia – Drug Profile
• Small Molecule to Agonize CB1 and CB2 for Fibromyalgia and Chronic
  Pain – Drug Profile
• Vaccine for Type 1 Diabetes and Fibromyalgia – Drug Profile
• VB-210 – Drug Profile
• VNP-101 – Drug Profile

Featured News & Press Releases

• Feb 12, 2019: Tetra Bio-Pharma provides update on its neuropathic and
  chronic pain drug development program
• Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for
  pharmaceutical grade cannabis-derived products
• Jan 28, 2019: Tetra Bio-Pharma files patent application to protect
  PPP001
• Dec 20, 2018: Tetra successfully completes phase 1 study with
  vaporized version of PPP001
• Dec 03, 2018: Aptinyx reports positive data from interim analysis of
  exploratory study of NYX-2925 in subjects with fibromyalgia
• Nov 01, 2018: Tetra Bio-Pharma obtains Health Canada approval to
  conduct a phase 1 pharmacokinetic & safety study using vaporized
  version of PPP001
• Oct 02, 2018: EpicGenetics Announces Important Reminders for
  Fibromyalgia Clinical Trial Eligibility
• Sep 14, 2018: Aptinyx Presents Preclinical Data on NMDA Receptor
  Modulator NYX-2925 at the International Association for the Study of
  Pain’s 17th World Congress on Pain
• Sep 05, 2018: FDA Approves Clinical Trial of Novel Treatment for
  Fibromyalgia
• Sep 03, 2018: Luye Pharma Group: Voluntary announcement class 1.1 new
  chemical drug LY03012 approved for clinical trial in China
• Jun 19, 2018: Luye Pharma Bolsters Its Global Analgesics Portfolio
  with China Class 1.1 New Compound LY03012 to Start Phase I Clinical
  Trials
• Jun 13, 2018: OWC Pharmaceutical Research Completes Development of
  Next Generation Orally-Disintegrating Tablet
• Aug 01, 2017: Aptinyx Initiates Phase 2 Clinical Studies Evaluating
  NYX-2925 in Two Chronic Pain Conditions
• Mar 22, 2017: Intec Pharma Initiates Phase I Trial of Accordion Pill
  for Cannabinoid Therapies
• Mar 07, 2017: Journal of Pain Research Publishes Results of PRID-201,
  a successful Phase 2 Trial using IMC-1 for the Treatment of
  Fibromyalgia

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/ktcc8c/fibromyalgia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Musculoskeletal
Disorders Drugs